N-isopropyl-p-123I Iodoamphetamine Single Photon Emission Computed Tomography Study of Parkinson's Disease with Dementia

Matsui, Hirokazu; Udaka, Fukashi; Miyoshi, Takafumi; Hara, Narihiro; Tamura, Akiko; Oda, Masaya; Kubori, Tamotsu; Nishinaka, Kazuto; Kameyama, Masakuni

doi:10.2169/internalmedicine.44.1046

Cited by 13 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, when compared with PD‐MCI patients, hypometabolism is more widespread in PDD patients, especially in the posterior cortical areas, and this heralds the progression to dementia in PD patients when considered in conjunction with the hypometabolism in the posterior cingulate and caudate nucleus . Moreover, impairment in specific cognitive domains is correlated with patterns of rCBF and hypometabolism in several studies . Furthermore, a recent study in a cohort of PDD patients with a multimodal PET approach show a correlation between hypometabolism, amyloid load, and microglial activation ([ 11 C]‐(R)PK11195 PET) in the anterior and posterior cingulate, striatum and frontal, temporal, parietal, and occipital cortical regions …”

Section: Pet and Single‐photon Emission Computed Tomography Imagingmentioning

confidence: 99%

“…2). In several studies, PDD and PD-MCI patients exhibit areas of reduced rCBF [234][235][236][237][238][239][240][241][242][243][244][245][246][247][248][249] and metabolism (more extensive in PDD), 212,[250][251][252][253][254][255][256][257][258] such as in the frontal, parietal, temporal, occipital and cingulate cortex, the basal ganglia, thalamus, and cerebellum. Interestingly, when compared with PD-MCI patients, hypometabolism is more widespread in PDD patients, especially in the posterior cortical areas, 251 and this heralds the progression to dementia in PD patients when considered in conjunction with the hypometabolism in the posterior cingulate and caudate nucleus.…”

Section: Imaging Brain Perfusion and Metabolismmentioning

confidence: 99%

“…259,260 Moreover, impairment in specific cognitive domains is correlated with patterns of rCBF and hypometabolism in several studies. 235,251,[261][262][263][264][265][266][267] Furthermore, a recent study in a cohort of PDD patients with a multimodal PET approach show a correlation between hypometabolism, amyloid load, and microglial activation ([ 11 C]-(R)PK11195 PET) in the anterior and posterior cingulate, striatum and frontal, temporal, parietal, and occipital cortical regions. 250 In summary, reduced rCBF and FDG uptake in the posterior cortical areas seems to be a useful biomarker of dementia in PD, 251 in line with functional and spectroscopic MRI data.…”

Section: Imaging Brain Perfusion and Metabolismmentioning

confidence: 99%

See 2 more Smart Citations

Biomarkers for dementia and mild cognitive impairment in Parkinson's disease

et al. 2016

View full text Add to dashboard Cite

Cognitive decline is one of the most frequent and disabling non-motor features of Parkinson´s disease. Around 30% of patients with Parkinson's disease experience mild cognitive impairment, a well-established risk factor for the development of dementia.However, mild cognitive impairment in patients with Parkinson's disease is a heterogeneous entity that involves different types and extents of cognitive deficits. Since it is not currently known which type of mild cognitive impairment confers a higher risk of progression to dementia, it would be useful to define biomarkers that could identify these patients to better study disease progression and possible interventions. In this sense, the identification among patients with Parkinson's disease and mild cognitive impairment of biomarkers associated with dementia would allow the early detection of this process. This review summarizes studies from the last 25 years that have assessed potential biomarkers of dementia and mild cognitive impairment in Parkinson's disease patients. Despite the potential importance, no biomarker has as yet been validated. However, features such as low levels of epidermal and insulin-like growth factors or uric acid in plasma/serum and of Aß in CSF, reduction of cerebral cholinergic innervation and metabolism measured by 3 PET mainly in posterior areas, and hippocampal atrophy in MRI might be indicative of dementia or of subgroups of patients with distinct subtypes of cognitive deficits with a distinct risk of dementia. Therefore, longitudinal studies combining the existing techniques and new approaches will be needed to identify patients at higher risk of dementia.

show abstract

Section: Pet and Single‐photon Emission Computed Tomography Imagingmentioning

confidence: 99%

Section: Imaging Brain Perfusion and Metabolismmentioning

confidence: 99%

Section: Imaging Brain Perfusion and Metabolismmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for dementia and mild cognitive impairment in Parkinson's disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Functional imaging studies, such as single photon emission computed tomography (SPECT), positron emission tomography (PET), magnetic resonance spectroscopy, and diffusion tensor imaging have been proposed in studying AD, PD and PDD [8, 11, 12, 15–17, 27]. It has been demonstrated that SPECT may not be a useful tool in the clinical differential diagnosis among PD, PDD and lewy body dementia and poor signal-to-noise ratios of the MRI techniques ultimately limits their sensitivity and reproducibility.…”

Section: Introductionmentioning

confidence: 99%

T1rho (T1ρ) MR imaging in Alzheimer’ disease and Parkinson’s disease with and without dementia

et al. 2010

View full text Add to dashboard Cite

In the current study, we aim to measure T1rho (T1ρ) in the hippocampus in the brain of control, Alzheimer’s disease (AD), Parkinson’s disease (PD), and PD patients with dementia (PDD), and to determine efficacy of T1ρ in differentiating these cohorts. With informed consent, 53 AD patients, 62 PD patients, 11 PDD patients, and 46 age-matched controls underwent a standardized clinical assessment including mini-mental state examination (MMSE) and brain T1ρ MRI on a 1.5-T clinical-scanner. T1ρ maps were generated by fitting each pixel’s intensity as a function of the spin-lock pulse duration. In control, AD, PD and PDD, mean ± SE T1ρ values in the right hippocampus (RH) were 92.15 ± 2.00, 99.65 ± 1.98, 85.68 ± 1.87, 102.47 ± 4.66 ms while in the left hippocampus (LH) these values were 90.16 ± 1.82, 99.53 ± 1.91, 84.33 ± 2.03, 95.33 ± 4.64 ms. Significant difference for both RH and LH T1ρ across the groups (p < 0.001) was observed. Both RH and LH T1ρ were significantly increased in AD compared to control (p = 0.034, p = 0.001) and PD (p < 0.001, p < 0.001). In control, both RH and LH T1ρ values were significantly increased compared to PD (p = 0.031, p = 0.027) while compared to PDD only the RH T1ρ value was significantly decreased (p = 0.043). Both RH and LH T1ρ values in PD were significantly lower than PDD (p = 0.004, p = 0.032). No significant correlation between the T1ρ and age as well as between T1ρ and MMSE scores was observed. The serial measurement of T1ρ in both AD and PD may provide the nature of disease progression and may contribute to their early diagnosis.

show abstract

“…Numerous studies during the last decade have attempted to investigate differences and associations between cortical perfusion, nigrostriatal dopamine pathway and neuropsychological functions in demented and non demented patients with PD. These studies show a tendency towards increased hypoperfusion in parietal and temporal lobes in PDD as compared to the non demented PD patients (Derejko et al, 2006;Liu et al, 1992;Matsui et al, 2005).There are also conflicting results in the literature regarding PD patients with MCI ranging from either no difference compared to controls (Sawada et al,1992;Spampinato et al, 1991) to hypoperfusion in the parietal (Wallin et al, 2007) and frontal areas (Antonini et al, 2001;Firbank et al, 2005;Paschali et al, 2009). Regarding rCBF and neuropsychological functions in different stages of PD, as dopaminergic nerve endings degenerate in PD there is progressive cortical hypoperfusion affecting mainly the frontal lobes in the early stages, extending to the parietal and temporal lobes in the late stages of Parkinson's disease.…”

mentioning

confidence: 87%